ZURICH (Reuters) – Lonza is investing in new drug product manufacturing capacity at its site in Guangzhou, China, the Swiss company said on Monday.
The sterile, multi-product fill and finish line is expected to be completed in 2022 and will create more than 150 jobs. Lonza, which has been making ingredients for Moderna’s COVID-19 vaccine, did not say how much it was spending on the Guangzhou plant.
(Reporting by John Revill; Editing by Michael Shields)
Djokovic says he’s ‘fine’ after being hit on the head by a water bottle
Emotional Mbappé confirms he will leave PSG ahead of an expected move to Real Madrid
Djokovic wins his opener at the Italian Open after a month off. Defending champ Rybakina withdraws
Korda shoots 66 to keep bid alive for 6th straight LPGA Tour win. She trails Zhang, Sagstom by 4
Paul Skenes is ready to deliver on the hype as prized Pirates rookie prepares for major league debut
It’s not a matter of if a hurricane will hit Florida, but when, forecasters say
Specialty lab exec gets 10-year prison term for 11 deaths from tainted steroids in Michigan
Ethics review finds probable cause that Rep. Troy Nehls misused campaign funds
Justice Kavanaugh says unpopular rulings can later become ‘fabric of American constitutional law’
US pledges money and other aid to help track and contain bird flu on dairy farms
